## Mankind Pharma Limited (MANKIND) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Mankind Pharma Limited (MANKIND) operates in the Pharmaceuticals industry.  It was listed on the Indian stock exchanges on May 9, 2023.  While specific market positioning within the sector requires further research beyond the provided data, its recent IPO and subsequent performance indicate a significant presence in the Indian pharmaceutical market.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹2,800.00       | Closed at ₹2,800.00, down from the previous close.                  |
| Percentage Change (PChange) | -3.15%          | Significant negative daily change.                                   |
| Pre-Open Activity          | ₹2,907.80       | Opened higher than the previous close, indicating initial buying interest. |
| Week High                   | ₹2,922.90       | Indicates recent price strength.                                     |
| Week Low                    | ₹1,851.05       | Shows significant price volatility over the week.                    |
| VWAP                        | ₹2,834.73       | Volume Weighted Average Price suggests a slightly higher average trading price. |
| Sector PE                   | 54.51           | Relatively high compared to the sector average (requires further context). |
| Symbol PE                   | 54.51           | Same as sector PE, indicating alignment with sector valuation.       |
| Delivery Percentage         | 41.45%          | Moderate delivery percentage, suggesting a mix of long-term and short-term investors. |
| Market Depth                | Limited Data    | The provided order book data shows zero buy and sell quantities, which is unusual and may indicate incomplete data or a quiet market at the time of data capture. Further investigation is needed. |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the last five quarters, although the figures are unaudited for the most recent quarters.  However, there's a notable decline in net sales and profit from Q1 2024 onwards.

| Quarter      | Revenue (₹)     | Expenses (₹)    | PAT (₹)         | EPS (₹)       |
|--------------|-----------------|-----------------|-----------------|----------------|
| Q1 2024 (Apr-Jun) | 249,809         | 192,072         | 51,349          | 12.09          |
| Q2 2024 (Jul-Sep) | 263,550         | 186,505         | 63,443          | 15.04          |
| Q3 2023 (Oct-Dec) | 242,579.67      | 184,944.51      | 48,707.33       | 12.16          |
| Q4 2023 (Jan-Mar) | 223,654.05      | 169,168.08      | 45,416.97       | 11.34          |
| Q1 2023 (Jul-Sep) | 251,146.35      | 189,950.11      | 47,288.44       | 11.80          |


**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.  The provided data only allows for a basic assessment of profitability.

**4. Corporate Actions and Announcements:**

Recent announcements include Qualified Institutional Placements (QIPs), allotment of securities, and general updates.  There are no declared dividends or splits mentioned in the provided data.  The numerous announcements suggest a high level of corporate activity, which could be positive or negative depending on the specifics of each announcement.  Further investigation into the nature of these announcements is crucial.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023  | 76.50                        | 23.50      | 0.00               | 100.00    |
| 31-Dec-2023  | 76.50                        | 23.50      | 0.00               | 100.00    |
| 31-Mar-2024  | 74.88                        | 25.12      | 0.00               | 100.00    |
| 30-Jun-2024  | 74.87                        | 25.13      | 0.00               | 100.00    |
| 30-Sep-2024  | 74.87                        | 25.13      | 0.00               | 100.00    |

Promoter holding has slightly decreased over the past year, while public holding has increased correspondingly. This could indicate a shift in investor sentiment or corporate actions.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The CM Annual Volatility of 35.34% further confirms this.  The risk-reward profile is currently skewed towards higher risk due to this volatility and the recent decline in financial performance.

**7. Advantages of Buying the Stock:**

* Strong promoter holding (although decreasing).
* Presence in a growing pharmaceutical market.
* Recent corporate actions (require further investigation to determine positive or negative impact).

**8. Disadvantages and Risks:**

* High volatility.
* Recent decline in financial performance (Q1 and Q2 2024).
* Limited market depth data.
* Unclear impact of recent corporate actions.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The recent price drop and high volatility make a short-term investment risky.  The lack of clear short-term catalysts further supports this recommendation.

* **Medium-term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The medium-term outlook depends heavily on the company's ability to reverse the recent decline in financial performance and the outcome of the various corporate actions.  Further investigation is needed before recommending a buy.

* **Long-term (1 year and beyond): Hold (if you have stock), Don't Buy (if you don't).**  Long-term prospects depend on the company's ability to maintain its market position and deliver consistent financial growth within the pharmaceutical sector.  However, given the current uncertainties, a buy recommendation is not justified at this time.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6/10**

* Financial Health: 5/10 (Recent decline in performance is concerning)
* Market Performance: 4/10 (High volatility and recent price drop)
* Volatility and Risk: 3/10 (High volatility is a significant risk)
* Corporate Actions & Governance: 7/10 (High activity, but impact unclear)
* Shareholding Patterns: 7/10 (Strong promoter holding, but decreasing)

**Analysis Score (out of 10): 8/10**

* Completeness and Data Utilization: 9/10 (Most data used effectively)
* Accuracy and Clarity: 8/10 (Analysis is clear, but some assumptions made due to incomplete data)
* Professional Formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, Mankind Pharma Limited (MANKIND) presents a mixed investment outlook.  While the company operates in a promising sector and has a relatively strong promoter holding, recent financial performance has declined, and the stock exhibits high volatility.  Until further clarification on the impact of recent corporate actions and a demonstration of improved financial performance, a "Don't Buy" recommendation is given for both short-term and long-term investment horizons.  If an investor already holds the stock, a "Hold" recommendation is given, pending further analysis and clarification of the company's future trajectory.  Further research is strongly recommended before making any investment decisions.
